BE study design and evaluation MCQs With Answer

BE study design and evaluation MCQs With Answer

This quiz collection is tailored for M.Pharm students studying Advanced Biopharmaceutics & Pharmacokinetics (MPH 202T). It focuses on the design, conduct, statistical analysis and regulatory interpretation of bioequivalence (BE) studies. Questions explore crossover and replicate designs, statistical tests (TOST, ANOVA), log-transformation, acceptance limits, reference-scaling for highly variable drugs, sample size considerations, fed versus fasting studies, steady-state and truncated AUC, dissolution similarity (f2) and biowaivers under the BCS. Each question is designed to deepen conceptual understanding and connect theory with regulatory practice, helping students prepare for exams and real-world BE study applications.

Q1. What is the primary objective of a bioequivalence (BE) study?

• To determine absolute bioavailability against an intravenous reference
• To compare formulation stability under accelerated conditions
• To demonstrate similar rate and extent of absorption between test and reference using AUC and Cmax
• To assess pharmacodynamic equivalence using clinical endpoints

Correct Answer: To demonstrate similar rate and extent of absorption between test and reference using AUC and Cmax

Q2. Which study design is most commonly used for single-dose BE studies of immediate-release oral products?

• Parallel group design with three arms
• Randomized two-period two-sequence crossover design
• Single-arm open-label ascending dose study
• Multiple-dose steady-state parallel design

Correct Answer: Randomized two-period two-sequence crossover design

Q3. Which statistical approach is routinely used to assess BE for log-transformed AUC and Cmax?

• Two-sided 95% confidence interval on arithmetic means
• Student’s paired t-test on raw values
• Two one-sided tests (TOST) using 90% confidence interval of geometric mean ratios
• Chi-square test comparing categorical response rates

Correct Answer: Two one-sided tests (TOST) using 90% confidence interval of geometric mean ratios

Q4. What are the conventional regulatory BE acceptance limits for the 90% confidence interval of the geometric mean ratio for AUC and Cmax?

• 70.00% – 143.00%
• 75.00% – 133.33%
• 80.00% – 125.00%
• 90.00% – 111.11%

Correct Answer: 80.00% – 125.00%

Q5. Why are PK metrics such as AUC and Cmax usually log-transformed before statistical analysis in BE studies?

• To make interpretation as arithmetic differences easier
• To normalize skewed distributions, stabilize variance and allow ratio-based inference
• To convert concentrations into percentages for regulatory reporting
• To eliminate the need for ANOVA and use nonparametric tests

Correct Answer: To normalize skewed distributions, stabilize variance and allow ratio-based inference

Q6. How is a highly variable drug (HVD) commonly defined for BE considerations?

• Within-subject coefficient of variation (CV) ≥ 30%
• Between-subject CV > 50%
• Half-life exceeding 24 hours
• Low therapeutic index with narrow safety margin

Correct Answer: Within-subject coefficient of variation (CV) ≥ 30%

Q7. What is a principal advantage of a replicate crossover design in BE studies?

• It eliminates the need for fasting conditions
• It allows direct estimation of within-subject variability for both test and reference
• It shortens study duration by reducing washout periods to zero
• It removes sequence and period effects by design

Correct Answer: It allows direct estimation of within-subject variability for both test and reference

Q8. Reference-scaled average bioequivalence is primarily used to:

• Widen BE acceptance limits for highly variable drugs based on reference variability
• Permit arithmetic mean comparisons without log transformation
• Replace in vivo studies with in vitro dissolution testing
• Relax sample size requirements unconditionally

Correct Answer: Widen BE acceptance limits for highly variable drugs based on reference variability

Q9. In which situation is a parallel group design preferred over a crossover for BE studies?

• When within-subject variability is negligible
• When the drug has a very long half-life or carryover makes crossover impractical
• For immediate-release products with short half-lives
• For highly variable drugs where reference-scaling is required

Correct Answer: When the drug has a very long half-life or carryover makes crossover impractical

Q10. For steady-state BE studies of chronic oral dosing, which PK parameters are most commonly compared?

• AUC0–∞ and apparent volume of distribution
• AUC over the dosing interval at steady state (AUCtau) and Cmax at steady state
• Single-dose Tmax and half-life only
• Total clearance and bioavailability F

Correct Answer: AUC over the dosing interval at steady state (AUCtau) and Cmax at steady state

Q11. What does a dissolution similarity factor (f2) ≥ 50 indicate?

• Test product dissolves at half the rate of reference
• Dissolution profiles of test and reference are similar enough for some regulatory biowaivers
• Immediate release formulation fails similarity
• In vitro profiles cannot be used to predict in vivo behavior

Correct Answer: Dissolution profiles of test and reference are similar enough for some regulatory biowaivers

Q12. How is a possible carryover effect commonly detected in a two-period crossover BE study?

• By comparing pre-dose concentrations only
• By inspecting a significant sequence or period effect in the ANOVA
• By checking Tmax distributions alone
• By performing a Kaplan–Meier survival analysis

Correct Answer: By inspecting a significant sequence or period effect in the ANOVA

Q13. When is truncated AUC (e.g., AUC0–t where t < infinity) typically used in BE analysis?

• When a single-dose study achieves full washout in two sampling points
• When complete AUC to infinity cannot be reliably estimated due to long half-life or limited sampling
• When Tmax occurs after the last sample time
• Only for topical and inhalation products

Correct Answer: When complete AUC to infinity cannot be reliably estimated due to long half-life or limited sampling

Q14. Under what circumstances is a fed-state BE study required by regulators?

• Never; fed-state studies are optional for all oral products
• Only when the product is an intravenous formulation
• When the label indicates dosing with food or when food significantly affects absorption
• When the test product has a shorter shelf life than reference

Correct Answer: When the label indicates dosing with food or when food significantly affects absorption

Q15. Which parameters are essential inputs for sample size calculation in a BE study?

• Within-subject CV, expected test/reference ratio, alpha level and desired power
• Only the drug’s therapeutic index and safety margins
• Number of available treatment arms and number of sites
• Only prior observed Tmax values and elimination half-life

Correct Answer: Within-subject CV, expected test/reference ratio, alpha level and desired power

Q16. For narrow therapeutic index (NTI) drugs, regulatory BE acceptance intervals for AUC are typically:

• Wider than 80–125% to increase generic availability
• Narrowed, for example 90.00%–111.11%, to ensure tight exposure control
• Not applied; NTI drugs are exempt from BE requirements
• Defined as 70.00%–143.00% for increased flexibility

Correct Answer: Narrowed, for example 90.00%–111.11%, to ensure tight exposure control

Q17. The regulatory criterion for demonstrating BE is most precisely stated as:

• The point estimate of the test/reference ratio must equal 1.00
• The 90% confidence interval for the geometric mean ratio must be contained within the predefined BE limits
• The Tmax distributions must be identical between products
• Mean concentrations at every time point must be within 10%

Correct Answer: The 90% confidence interval for the geometric mean ratio must be contained within the predefined BE limits

Q18. Which PK parameter is the principal indicator of the extent of absorption in BE studies?

• Cmax
• Tmax
• AUC
• Elimination half-life (t1/2)

Correct Answer: AUC

Q19. What is a principal regulatory use of an in vitro–in vivo correlation (IVIVC)?

• To replace all clinical safety studies for new chemical entities
• To predict plasma concentration-time profiles from dissolution and potentially support formulation changes or biowaivers
• To determine batch-to-batch microbial contamination
• To define the drug’s pharmacodynamic potency

Correct Answer: To predict plasma concentration-time profiles from dissolution and potentially support formulation changes or biowaivers

Q20. Under BCS-based biowaiver guidance, which class of drugs is most commonly eligible for waiver of in vivo BE studies?

• BCS Class II (low solubility, high permeability) always
• BCS Class I (high solubility, high permeability) and under some conditions Class III
• Only injectable formulations
• BCS Class IV (low solubility, low permeability) with rapid dissolution

Correct Answer: BCS Class I (high solubility, high permeability) and under some conditions Class III

Download